-
公开(公告)号:US20240123055A1
公开(公告)日:2024-04-18
申请号:US18380479
申请日:2023-10-16
Applicant: Longhorn Vaccines and Diagnostics, LLC
Inventor: Gerald W. Fischer , Clara J. Sei , Jeffrey D. Fischer
IPC: A61K39/215 , A61K39/015 , A61K39/04 , A61K39/085 , A61K39/145 , A61K39/21 , A61P31/04 , A61P31/12 , A61P31/16 , C07K14/005 , C07K16/08 , C07K16/12 , C07K16/20 , C08G69/10 , C12N5/16 , C12N7/00
CPC classification number: A61K39/215 , A61K39/015 , A61K39/04 , A61K39/085 , A61K39/145 , A61K39/21 , A61P31/04 , A61P31/12 , A61P31/16 , C07K14/005 , C07K16/08 , C07K16/12 , C07K16/205 , C08G69/10 , C12N5/16 , C12N7/00 , A61K2039/55544 , C12N2760/16022 , C12N2760/16034 , C12N2760/16071 , C12N2770/20022 , C12N2770/20034 , C12N2770/20071
Abstract: The invention relates to compositions and peptides or peptide sequences that induce an immune response in an animal or a mammal that is protective against infection by one or more pathogens. In addition, the invention relates to immunogenic composition and vaccines comprising compositions and peptide sequences and to method for treating and preventing an infection in animals and mammals such as humans and antibodies.
-
公开(公告)号:US20180333478A1
公开(公告)日:2018-11-22
申请号:US15893261
申请日:2018-02-09
Applicant: KJ Biosciences LLC
Inventor: Yawei Ni
IPC: A61K39/145 , C07K14/47 , A61K39/12 , A61K39/21 , A61K39/39 , C07K14/005 , C07K14/11 , C07K14/195 , C07K14/245 , A61K39/00 , C12N7/00
CPC classification number: A61K39/145 , A61K39/0011 , A61K39/12 , A61K39/21 , A61K39/39 , A61K2039/55555 , A61K2039/55566 , A61K2039/6068 , C07K14/005 , C07K14/11 , C07K14/195 , C07K14/245 , C07K14/4748 , C07K2319/00 , C07K2319/33 , C12N7/00 , C12N2710/20022 , C12N2710/20034 , C12N2740/16122 , C12N2760/16022 , C12N2760/16034 , C12N2760/16071 , C12N2760/16122
Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.
-
公开(公告)号:US20180099032A1
公开(公告)日:2018-04-12
申请号:US15705520
申请日:2017-09-15
Applicant: UNIVERSITY OF MIAMI
Inventor: Pirouz Mohammad Daftarian , Paolo Serafini , Vance Paul Lemmon , Wei Li , Angel Kaifer , Bonnie Beth Blomberg , Victor L. Perez
IPC: A61K39/00 , A61K39/12 , A61K39/145 , C08G83/00
CPC classification number: A61K39/0011 , A61K39/12 , A61K39/145 , A61K2039/53 , A61K2039/55516 , A61K2039/55555 , A61K2039/645 , C08G83/006 , C12N2760/16022 , C12N2760/16034 , G01N2333/70539
Abstract: Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle-based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer.
-
公开(公告)号:US09889190B2
公开(公告)日:2018-02-13
申请号:US14967729
申请日:2015-12-14
Applicant: KJ Biosciences LLC
Inventor: Yawei Ni
IPC: A61K39/145 , A61K39/39 , C07K14/11 , C07K14/195 , A61K39/12 , A61K39/21 , C07K14/245 , C07K14/005 , A61K39/00 , C07K14/47 , C12N7/00
CPC classification number: A61K39/145 , A61K39/0011 , A61K39/12 , A61K39/21 , A61K39/39 , A61K2039/55555 , A61K2039/55566 , A61K2039/6068 , C07K14/005 , C07K14/11 , C07K14/195 , C07K14/245 , C07K14/4748 , C07K2319/00 , C07K2319/33 , C12N7/00 , C12N2710/20022 , C12N2710/20034 , C12N2740/16122 , C12N2760/16022 , C12N2760/16034 , C12N2760/16071 , C12N2760/16122
Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.
-
5.
公开(公告)号:US20170173147A1
公开(公告)日:2017-06-22
申请号:US15448077
申请日:2017-03-02
Applicant: Advanced BioNutrition Corp.
Inventor: MORDECHAI HAREL , BRIAN CARPENTER
CPC classification number: A61K39/39 , A61K9/0043 , A61K9/006 , A61K9/5015 , A61K39/00 , A61K39/0208 , A61K39/0233 , A61K39/0241 , A61K39/12 , A61K39/145 , A61K39/21 , A61K2039/522 , A61K2039/5254 , A61K2039/5258 , A61K2039/541 , A61K2039/542 , A61K2039/543 , A61K2039/552 , A61K2039/55555 , A61K2039/55583 , C12N7/00 , C12N2720/10011 , C12N2720/10023 , C12N2720/10034 , C12N2740/10011 , C12N2740/10034 , C12N2760/10034 , C12N2760/16011 , C12N2760/16022 , C12N2760/16034
Abstract: The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.
-
6.
公开(公告)号:US20160136259A1
公开(公告)日:2016-05-19
申请号:US15005950
申请日:2016-01-25
Applicant: CureVac AG
Inventor: Florian Von Der Mülbe , Ingmar Hoerr , Steve Pascolo
CPC classification number: A61K48/005 , A61K38/1735 , A61K38/1816 , A61K38/19 , A61K38/193 , A61K38/28 , A61K39/00 , A61K39/0011 , A61K39/0258 , A61K39/12 , A61K39/145 , A61K39/21 , A61K47/542 , A61K47/6455 , A61K48/00 , A61K48/0066 , A61K48/0075 , A61K48/0083 , A61K2039/53 , C07K14/005 , C07K14/245 , C07K14/4727 , C07K14/4748 , C12N7/00 , C12N15/11 , C12N15/67 , C12N2310/334 , C12N2310/336 , C12N2740/16022 , C12N2740/16034 , C12N2760/14122 , C12N2760/14134 , C12N2760/16022 , C12N2760/16034 , C12N2760/16071 , C12N2770/24122 , C12N2770/24134 , G16B20/00 , G16B30/00 , Y02A50/386 , Y02A50/388 , Y02A50/416 , Y02A50/464 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
-
7.
公开(公告)号:US20160136243A1
公开(公告)日:2016-05-19
申请号:US15005753
申请日:2016-01-25
Applicant: CureVac AG
Inventor: Florian Von Der Mülbe , Ingmar Hoerr , Steve Pascolo
CPC classification number: A61K48/005 , A61K38/1735 , A61K38/1816 , A61K38/19 , A61K38/193 , A61K38/28 , A61K39/00 , A61K39/0011 , A61K39/0258 , A61K39/12 , A61K39/145 , A61K39/21 , A61K47/542 , A61K47/6455 , A61K48/00 , A61K48/0066 , A61K48/0075 , A61K48/0083 , A61K2039/53 , C07K14/005 , C07K14/245 , C07K14/4727 , C07K14/4748 , C12N7/00 , C12N15/11 , C12N15/67 , C12N2310/334 , C12N2310/336 , C12N2740/16022 , C12N2740/16034 , C12N2760/14122 , C12N2760/14134 , C12N2760/16022 , C12N2760/16034 , C12N2760/16071 , C12N2770/24122 , C12N2770/24134 , G16B20/00 , G16B30/00 , Y02A50/386 , Y02A50/388 , Y02A50/416 , Y02A50/464 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
-
8.
公开(公告)号:US20160095917A1
公开(公告)日:2016-04-07
申请号:US14967729
申请日:2015-12-14
Applicant: KJ Biosciences LLC
Inventor: Yawei Ni
IPC: A61K39/145 , A61K39/12 , A61K39/00 , C07K14/195 , A61K39/21 , C07K14/47 , C12N7/00 , C07K14/245
CPC classification number: A61K39/145 , A61K39/0011 , A61K39/12 , A61K39/21 , A61K39/39 , A61K2039/55555 , A61K2039/55566 , A61K2039/6068 , C07K14/005 , C07K14/11 , C07K14/195 , C07K14/245 , C07K14/4748 , C07K2319/00 , C07K2319/33 , C12N7/00 , C12N2710/20022 , C12N2710/20034 , C12N2740/16122 , C12N2760/16022 , C12N2760/16034 , C12N2760/16071 , C12N2760/16122
Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.
Abstract translation: 提供了包含与Dps(来自饥饿细胞的DNA结合蛋白)融合的蛋白质或肽的新型纳米颗粒融合蛋白,其为开发新的和改进的疫苗,诊断测试和其他生物医学产品带来明显的优点。
-
公开(公告)号:US20160068573A1
公开(公告)日:2016-03-10
申请号:US14853894
申请日:2015-09-14
Applicant: Aileron Therapeutics, Inc.
Inventor: Huw M. Nash , David Allen Annis
IPC: C07K7/08
CPC classification number: A61K38/10 , A61K38/00 , C07K7/06 , C07K7/08 , C07K7/54 , C07K7/56 , C07K7/64 , C07K14/005 , C12N2760/16022
Abstract: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease.
-
公开(公告)号:US20150374813A1
公开(公告)日:2015-12-31
申请号:US14733632
申请日:2015-06-08
Applicant: NOVAVAX, INC.
Inventor: Gale SMITH , Rick BRIGHT , Peter M. PUSHKO , Jinyou ZHANG , Kutub MAHMOOD
IPC: A61K39/145 , C12N7/00
CPC classification number: A61K39/145 , A61K39/12 , A61K2039/5258 , A61K2039/543 , A61K2039/55505 , A61K2039/55555 , A61K2039/55561 , A61K2039/58 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N2710/14143 , C12N2760/16022 , C12N2760/16023 , C12N2760/16034 , C12N2760/16122 , C12N2760/16123 , C12N2760/16134
Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
Abstract translation: 本发明公开并要求从具有大流行潜力的病毒中表达和/或含有季节性流感病毒蛋白,禽流感病毒蛋白和/或流感病毒蛋白质的病毒样颗粒(VLPs)。 本发明包括包含所述蛋白质的载体构建体,包含所述构建体的细胞,制剂和包含本发明的VLP的疫苗。 本发明还包括制备和施用VLP到脊椎动物的方法,包括诱导季节性和禽流感的实质性免疫或其至少一种症状的方法。
-
-
-
-
-
-
-
-
-